Hem › Diffust storcelligt B-cellslymfom › Pennsylvania › Philadelphia
Kliniska studier för Diffust storcelligt B-cellslymfom i Philadelphia, PA
15 studier för Diffust storcelligt B-cellslymfom söker deltagare vid platser i och runt Philadelphia (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekryterarFas 2
- Fox Chase Cancer Center, Philadelphia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekryterarObservationsstudie
- Children's Hospital of Philadelphia, Philadelphia
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RekryterarFas 2
- Thomas Jefferson University Hospital, Philadelphia
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RekryterarFas 2/3
- Alliance Cancer Specialists (ACS) ( Site 8001), Horsham · 16 mi bort
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RekryterarFas 2
- Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131), Philadelphia
- Temple University Hospital ( Site 0133), Philadelphia
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekryterarFas 1
- University of Pennsylvania Abramson Cancer Center, Philadelphia
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekryterarFas 1/2
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RekryterarFas 1/2
- Thomas Jefferson University, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekryterarFas 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RekryterarFas 1
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekryterarFas 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
RekryterarFas 1
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RekryterarFas 2
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia
SynKIR-310 for Relapsed/Refractory B-NHL
RekryterarFas 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
RekryterarFas 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Diffust storcelligt B-cellslymfom-studier i andra städer
- New York City, NY21 studier
- Baldwin Park, CA19 studier
- Chicago, IL18 studier
- Los Angeles, CA17 studier
- Houston, TX17 studier
- Boston, MA16 studier
- Milwaukee, WI16 studier
- Portland, OR15 studier
- Nashville, TN15 studier
- Durham, NC14 studier
- Dallas, TX13 studier
- Seattle, WA12 studier
Andra studier i Philadelphia
- Cancer (alla typer)59 studier
- Bröstcancer56 studier
- Icke-småcellig lungcancer51 studier
- Metastaserande cancer46 studier
- Kolorektal cancer44 studier
- Äggstockscancer44 studier
- Prostatacancer44 studier
- Lungcancer36 studier
- Akut myeloid leukemi34 studier
- Hjärtsvikt31 studier
- Endometriecancer28 studier
- Depression26 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.